Corporate partnerships are a key component of Ambit's strategy to discover and develop best-in-class kinase inhibitors for the treatment of cancer and other diseases. Our existing collaborations with major pharmaceutical companies validate Ambit's approach to kinase drug discovery, and the value that this approach offers in quickly moving products from discovery into the clinic.
Ambit's partnering strategy has three distinct components to maximize the value of its discovery capabilities and development assets:
- Oncology products. We seek to retain rights through discovery and early clinical development, and partner upon demonstrating clinical proof of concept.
- Non-oncology products. We seek to partner in preclinical or early clinical development.
- Collaborative research. Through strategic collaborations, we apply our accelerated approach to kinase drug discovery and our proprietary know-how to help partners maximize the value of their kinase-focused small molecule libraries.
For further information on partnering with Ambit on our development-stage projects, or strategic research partnerships, please contact firstname.lastname@example.org